I have three data points across nine months, which I hope is enough to see a trend.
I can parse the result. I am less sure what it licenses me to conclude.
I have deliberately not looked at anyone else’s interpretation yet.
Which parts of this are informative and which are decoration?
Answer first: most of the metabolic evidence here is indirect, drawn from insulin-resistance and weight endpoints in populations that overlap with this one rather than from dedicated trials.
Weight reduction of five to ten per cent has been associated in the older literature with restored ovulatory function in a meaningful fraction of people with this diagnosis, which is the mechanistic bridge the current interest rests on.
Insulin resistance measured by HOMA-IR improves alongside weight in this class, and HOMA-IR is a fasting-sample surrogate rather than a clamp measurement — adequate for tracking, weak for comparing across studies.
Dedicated randomised evidence for this class in this diagnosis is limited and mostly small; the strong evidence is for the metabolic endpoints in adjacent populations.
The mechanism is plausible; the direct evidence is thin. Both statements are true at once.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsOn the detail: the relevant mechanism is insulin resistance and its effect on ovarian androgen production, which is why a weight and insulin-sensitivity intervention has a plausible route to the reproductive phenotype.
Metformin remains the comparator with the longest evidence base in this condition, and any claim that a newer agent is superior needs a head-to-head trial rather than cross-study comparison.
Hirsutism and acne respond on the timescale of the hair growth cycle, which is months, so early absence of change says nothing.
The relationship between insulin resistance and ovarian androgen production is well characterised mechanistically and is the basis for insulin-sensitising approaches generally.
Check which diagnostic criteria a study used before comparing it with another.
Start with the phenotype. This is a heterogeneous diagnosis with distinct presentations, and evidence about one presentation does not transfer cleanly to another.
Cycle regularity is a slow endpoint. Three to six months is the minimum window in which a change would be interpretable, and shorter studies are measuring noise.
On the detail: free androgen index responds to sex-hormone-binding globulin, which itself rises as insulin resistance falls. So an androgen improvement can appear without any change in total testosterone production, purely through the binding protein.
The evidence gap between metabolic and reproductive endpoints in this condition is real, and inference across it should be labelled as inference.
Separate metabolic, reproductive and dermatological endpoints before reading any claim about this condition.
edited 18 Aug 2025 by Dr_Aoife_Brennan — added the citation requested in comments
More usefully, this is an area where the mechanistic argument is stronger than the trial evidence, and it is worth saying so plainly rather than dressing up the inference.
The Rotterdam criteria allow several combinations of the three diagnostic features, so a study enrolling on one combination reports on a different population from one enrolling on another.
Guideline recommendations in this condition still put weight management and metformin ahead of newer agents, on evidence-base grounds rather than on mechanism.
Six months is the minimum honest window for a cycle-regularity claim.
It helps to be literal here: the diagnostic criteria themselves are contested, so studies using different criteria are not enrolling quite the same people.
Restored ovulation is a fertility consideration in both directions, and any discussion of this class in a population of reproductive age has to acknowledge the contraception question rather than route around it.
Free androgen changes can come from the binding protein rather than from production. Read both numbers.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.